症状性子宫肌瘤子宫动脉栓塞术五年临床结局:再干预危险因素分析
研究纳入92例连续症状性子宫肌瘤女性(平均年龄41.9岁),行双侧子宫动脉栓塞术,术后3个月行增强MRI,5年随访评估再干预率及预测因素。67例可评估患者中症状缓解率98.5%,中位随访60个月再干预率10.4%;优势肌瘤近完全或部分梗死(OR 22.238)及存在存活非优势肌瘤(OR 12.134)为再干预独立危险因素。
要点
- UAE术后5年再干预率为10.4%,症状缓解率98.5%。
- 优势肌瘤近完全或部分梗死(<90%)再干预风险OR 22.238。
- 存在存活非优势肌瘤再干预风险OR 12.134。
核心结论
- UAE对症状性子宫肌瘤提供优异且持续的症状改善,5年随访再干预率低;随访MRI显示优势肌瘤近完全或部分梗死及存在存活非优势肌瘤提示再干预风险更高。
研究设计与样本
- 2011年3月至2012年2月连续纳入92例症状性子宫肌瘤女性(平均年龄41.9岁,范围28-55岁)行双侧UAE,术后3个月行增强MRI,年度随访后于5年随访时进行临床结局与再干预调查,评估再干预预测因素。
关键影像表现/征象
- 优势肌瘤完全(100%)或近完全(90-99%)梗死率为96.4%(54/56)。
- 随访MRI显示优势肌瘤近完全或部分(<90%)梗死及存在存活非优势肌瘤与再干预相关。
诊断标准与关键数值
- 优势肌瘤近完全或部分(<90%)梗死预测再干预:OR 22.238(95%CI 2.405-205.620,p=0.006)。
- 存在存活非优势肌瘤预测再干预:OR 12.134(95%CI 1.213-121.409,p=0.034)。
临床应用与阅片要点
- UAE术后3个月增强MRI评估肌瘤梗死程度,优势肌瘤近完全或部分(<90%)梗死及存活非优势肌瘤提示再干预风险较高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The objective of this study is to investigate the five-year reintervention rate of uterine artery embolization (UAE) for symptomatic leiomyomas and to identify potential predictive factors of reintervention.
METHODS: From March 2011 to February 2012, 92 consecutive women (mean age 41.9 years, range 28-55 years) underwent bilateral UAE. Contrast-enhanced magnetic resonance imaging (MRI) was performed at three-month follow-up. After annual follow-up, a survey on clinical outcome and reintervention incidences was performed at five-year follow-up. Potential predictive factors of reintervention were evaluated.
RESULTS: Of the 67 patients, menorrhagia and/or bulk-related symptoms were resolved after UAE in all but one patient (98.5%). At median follow-up of 60 months (range, 5-60 months), reintervention rate was 10.4%, with seven reintervention cases (five myomectomy and two hysterectomy cases). Complete (100%) or near complete (90-99%) infarction rate of the dominant leiomyoma was 96.4% (54 of 56). Independent factors of reintervention on multivariate logistics regression analysis included near complete or partial (<90%) infarction of the dominant leiomyoma (odds ratio [OR] 22.238; 95% confidence interval [CI] 2.405-205.620; p = 0.006), as well as the presence of non-dominant viable leiomyomas (OR 12.134; 95% CI 1.213-121.409; p = 0.034).
CONCLUSION: UAE provides excellent and sustained symptom improvement of symptomatic leiomyomas with a low reintervention rate at five-year follow-up. In addition to near complete or partial infarction of the dominant leiomyoma on follow-up MRI, the presence of viable non-dominant leiomyomas indicates a higher risk of reintervention.
引用
- Yoon JK, Han K, Kim MD, et al. Five-year clinical outcomes of uterine artery embolization for symptomatic leiomyomas: An analysis of risk factors for reintervention. Eur J Radiol. 2018. PMID: 30527317. doi:10.1016/j.ejrad.2018.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。